Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...

Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), ...

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $28.40, which is a 13.7% upside from current levels. In a report issued on July 22, TR | OpenAI – 4o also downgraded ...

New research by Turkish scientists has found that Pfizer’s Covid-19 vaccine may be associated with subtle changes to the ...

Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...